's () chairman Tim McCarthy tells Proactive London's Andrew Scott discussions with potential partners are ongoing as they consider the best route forward for its lead drug.
The results from an extension study of Lupuzor, a treatment for the autoimmune disease Lupus, will factor into the decision making.
McCarthy also updates on plans to merge the Elro and Ureka subsidiaries and are looking to out-licence their technologies, or spin off the businesses completely.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE